There's a new home for news and congress coverage! Catch up on all the top stories and latest evidence in oncology research with our ESMO congress hub page.  Learn more »

Findings from the TARGET-TP trial support a risk-directed approach to thromboprophylaxis in ambulatory patients with gastrointestinal or lung cancer receiving systemic anticancer treatment.

AEs of grade 3 or higher occurred in 10.6% of patients in the SBRT plus AAP group and 15.8% of those in the AAP alone group, and there was no increase in the incidence of AEs considered potentially related to SBRT in the experimental versus control group, such as any-grade osteoporosis or fracture (2.7 vs 6.0%), hematuria (4.9 vs 5.3%), and gastrointestinal disorders (2.7 vs 1.2%).

The authors – a multidisciplinary group of experts from Europe, Australia, and the USA – address the diagnosis, treatment, and follow-up of the most common immunotherapy-related adverse events, including cardiovascular, dermatologic, gastrointestinal, neurologic, and pulmonary toxicities as well as endocrinopathies.

DOI [Teaser] Key Summary Points Colon cancer is one of the most common types of gastrointestinal cancer.

The current study included 273 cancer survivors aged an average of 61.1 years who had received platinum alone (12.8%), taxane alone (56.8%), or both (30.4%) for breast, gastrointestinal, gynecologic, or lung cancer.

Electronic patient-reported outcomes to monitor immune-related adverse events during immunotherapy for cancer is associated with a reduction in the incidence of serious adverse events, emergency department visits, and treatment discontinuations, and a better quality of life, research suggests.

The most common cancers included in the studies were gastrointestinal (26.1%), lung (20.5%), and leukemia (12.1%).

The majority (87%) of participants had stage IV disease and a third (34%) had gastrointestinal cancer, with lung (25%), genitourinary (15%), and breast cancer (8%) the next most common tumor types in the study population.

The most common malignancies were gastrointestinal (33.4%), breast (22.5%), lung (16.0%), genitourinary (15.0%), and gynecologic (8.9%) cancers.

The study included 20 patients – 15 with gastrointestinal cancers and five with breast cancer – who were receiving systemic cytotoxic therapy, most commonly gemcitabine-based regimens (50%).

Just under half (49.2%) of the patients had a diagnosis of lung cancer, with melanoma and genitourinary cancers the next most common diagnoses, at 11.9% and 11.2%, respectively.

The study included 95 patients with solid tumors – most commonly gastrointestinal (26%), lung (25%), and breast (18%) cancer – and 66 cancer-free individuals who received two doses of the Pfizer–BioNTech vaccine at an Israeli cancer center.

The majority (63.4%) of participants had solid tumors, most commonly breast or gynecologic cancers, followed by urologic cancers, gastrointestinal cancers, and thoracic malignancies, while 36.6% had hematologic cancers.

Serious adverse reactions occurred in 57% of patients, and were most commonly gastrointestinal events, particularly diarrhea.

Dose intensification does not improve the outcomes of salvage radiotherapy after radical prostatectomy, the SAKK 09/10 investigators have reported at the 2021 Genitourinary Cancers Symposium.

The most common cancer diagnoses were breast (37%), thoracic (25%), and gastrointestinal (18%), and 61% were receiving active anticancer treatment.

The multitargeted kinase inhibitor is indicated for advanced or metastatic renal cell carcinoma and several gastrointestinal tumor types.

Among 105 patients admitted to 14 hospitals in Hubei Province, China between 1 January and 24 February 2020, 21.0% had lung cancer, 12.4% had gastrointestinal cancer, 10.5% had breast cancer, 10.5% had thyroid cancer, 8.6% had hematologic cancer, and the remainder had other types of cancer.